DAMORA THERAPEUTICS, INC. Investing Cash Flow
DAMORA THERAPEUTICS, INC. (DMRA) reported Investing Cash Flow of -$17.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-06-30 was $6.00M, a 94.11% increase year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-03-31 was $5.65M, a 311.21% increase year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$17.37M, a 249.13% decline from fiscal 2024.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $11.65M, a 47.83% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $22.33M, a 80.31% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $12.38M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$17.37M 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $6.00M derived: sum of 3 quarters · filed 2026-03-19 | $11.65M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.00M derived: sum of 2 quarters · filed 2025-11-06 | $11.65M 10-Q · filed 2025-11-06 | $21.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $11.65M 10-Q · filed 2025-08-05 | $21.23M derived: sum of 3 quarters · filed 2025-08-05 | $29.52M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $5.65M 10-Q · filed 2025-05-08 | $15.23M derived: sum of 2 quarters · filed 2025-05-08 | $23.52M derived: sum of 3 quarters · filed 2025-05-08 | $26.61M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $17.86M derived: sum of 2 quarters · filed 2025-03-19 | $20.96M derived: sum of 3 quarters · filed 2025-03-19 | $22.33M 10-K · filed 2025-03-19 |
| 2023-09-30 | $8.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $11.38M derived: sum of 2 quarters · filed 2024-11-01 | $12.75M 10-Q · filed 2024-11-01 | $27.08M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $4.46M 10-Q · filed 2024-08-12 | $18.80M derived: sum of 3 quarters · filed 2024-08-12 | $27.11M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.37M 10-Q · filed 2024-04-29 | $15.70M derived: sum of 2 quarters · filed 2024-04-29 | $24.02M derived: sum of 3 quarters · filed 2024-04-29 | $23.96M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $14.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $22.64M derived: sum of 2 quarters · filed 2024-03-08 | $22.59M derived: sum of 3 quarters · filed 2024-03-08 | $12.38M 10-K · filed 2024-03-08 |
| 2022-09-30 | $8.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $8.26M derived: sum of 2 quarters · filed 2023-11-06 | -$1.95M 10-Q · filed 2023-11-06 | $12.47M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | -$10.26M 10-Q · filed 2023-07-31 | $4.15M derived: sum of 3 quarters · filed 2023-07-31 | $11.20M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | -$10.21M 10-Q · filed 2023-04-28 | $4.21M derived: sum of 2 quarters · filed 2023-04-28 | $11.25M derived: sum of 3 quarters · filed 2023-04-28 | $16.38M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $21.46M derived: sum of 2 quarters · filed 2023-03-09 | $26.58M derived: sum of 3 quarters · filed 2023-03-09 | -$48.05M 10-K · filed 2023-03-09 |
| 2021-09-30 | $7.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $12.17M derived: sum of 2 quarters · filed 2022-11-08 | -$62.46M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $5.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$69.51M 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | -$74.63M 10-Q · filed 2022-04-29 | |||
| 2019-12-31 | -$326.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |